Navigation Links
Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
Date:4/23/2012

PARAMUS, N.J., April 23, 2012 /PRNewswire/ -- Today, Asubio announced the initiation of a landmark Phase 2 clinical trial of SUN13837, an investigational medication being developed to improve neurological function in patients with newly diagnosed acute spinal cord injury.

In accordance with its internal focus on scientific rigor, Asubio recently discussed its endpoint development activities at a peer-attended symposium at the American Spinal Injury Association (ASIA) annual meeting. The company also reinforced its long-term strategic and financial commitment to completing the clinical trial.

Asubio is working with 60 acute trauma centers throughout the United States and Canada to enroll 164 patients in the clinical trial.  Trauma centers must first sign on to participate in the study, and then attending trauma physicians and nurses will identify eligible patients when they arrive at a facility with a spinal cord injury. Physicians or trauma center representatives can write Ben Levinson at blevinson@asubio.com for more information about participation, or visit ClinicalTrials.gov (NCT01502631).

"Valid clinical trial programs, such as the acute spinal cord injury study being supported by Asubio provide an objective path to understanding and improving life after spinal cord injury," said John Steeves, PhD, Peter Wall Distinguished Scholar in Residence, Professor and Founding Director of ICORD (International Collaboration On Repair Discoveries).  "I encourage all Level One Trauma Centers to consider informing and enrolling appropriate participants."

This randomized, placebo-controlled study will determine whether subjects receiving SUN13837 are more likely to improve by two or more motor levels from baseline on either their right or left side as determined using the International Standards for Neurological Classification of Spinal Cord Injury Scale.  Patients will be selecte
'/>"/>

SOURCE Asubio
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
2. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
3. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
6. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
7. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. Prolexys Pharmaceuticals Initiates Phase 1 Study
10. Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
11. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 Research and Markets ... Sclerosis Drugs Market 2014-2018" report to their offering. ... medical condition that results in demyelination, axonal transection, and ... abnormal response by the immune system, which targets neurons ... potentially debilitating disease in which the damage of the ...
(Date:8/29/2014)... 29, 2014 Pixcelldata, the innovative ... has announced a major new deal with Dutch based ... pathology expert, Dr. Marius Nap . ... European Congress of Pathology which is taking placing between ... London where Pixcelldata will demonstrate ...
(Date:8/28/2014)... 28, 2014  Rigrodsky & Long, P.A.: , ... (NYSE: LCI )? , Did you purchase your ... July 16, 2014, inclusive? , Did you lose money ... you want to discuss your rights? ... Attorney, Timothy J. MacFall , announces that a complaint has ...
Breaking Medicine Technology:Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3Pixcelldata Announces New Deal with Dutch Tele-Pathology Specialists eX-Path Ahead of ECP 2014 2Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 2Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 3
... Systems Ltd. (Nasdaq: DHRM ) ("Dehaier" or ... marketing and sale of medical devices and homecare medical ... Weibing Yang as and Dr. Genhui Chen directors of ... fills the vacancy resulting from the resignation of Ms. ...
...  Researchers have published the largest single patient population ... patients with retrievable inferior vena cava (IVC) filters—devices ... the lungs. This study, which is important for ... existing guidelines developed by the Society of Interventional ...
Cached Medicine Technology:Dehaier Medical Announces Changes to Board of Directors 2Dehaier Medical Announces Changes to Board of Directors 3IVC Filters: Society of Interventional Radiology Leads in Patient Care, Safety, Research 2IVC Filters: Society of Interventional Radiology Leads in Patient Care, Safety, Research 3IVC Filters: Society of Interventional Radiology Leads in Patient Care, Safety, Research 4
(Date:8/29/2014)... New ESC registries are being launched on cardiac ... comes as the long-term phase of the cardiomyopathy ... failure patients conducted in collaboration with the Organisation ... outcomes evaluation. , The registries are all part ... Professor Roberto Ferrari, Chairperson of EORP, said: "The ...
(Date:8/29/2014)... As a chiropractic physician and medical ... there’s a direct connection between the condition of the ... "Since conventional shoe inserts and orthotics weren’t satisfying my ... own," he said. , Customizable to a user’s needs, ... the foot in order to help prevent pain in ...
(Date:8/29/2014)... August 29, 2014 Glendale Botox ... promotion on Botox throughout the month of September. This special ... of two syringes of Juvederm. Patients can take advantage of ... skin. The Glendale Botox experts will work with patients to ... , What is Botox? , Botox is a ...
(Date:8/29/2014)... 2014 (HealthDay News) -- The main strain of ... East and North Africa originated in sub-Saharan Africa, ... community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) infections, ... recently been hospitalized. These infections typically affect the ... or through touching contaminated objects such as clothing ...
(Date:8/29/2014)... FRIDAY, Aug. 29, 2014 (HealthDay News) -- The way ... the baby,s language development, a new study suggests. ... mothers and their infants during free play. The sessions ... The infants were 8 months old at the start ... to a baby,s babbling, infants began to form complex ...
Breaking Medicine News(10 mins):Health News:New ESC registries launched on cardiac oncology and ACS 2Health News:New ESC registries launched on cardiac oncology and ACS 3Health News:New ESC registries launched on cardiac oncology and ACS 4Health News:Glenoaks Laser Center is Now Offering a Special Promotion on Botox for the Month of September 2Health News: European MRSA Originated in Sub-Saharan Africa, Study Finds 2Health News:Encouraging Your Baby's Babbling May Speed Language Development 2
... published in the November issue of the Springer journal ... absorptiometry has been cut to levels substantially below the ... physicians and clinics around the country are likely to ... access to the test and jeopardizing those at risk ...
... Employees,International Union (SEIU), the nation,s largest labor union for ... the diagnosis of,and prescription for mending our broken health ... On the heels of a historic election where voters ... health care costs as their number one,economic concern -- ...
... Regarding Protecting,Children from the Flu, ARLINGTON, Va., Nov. 12 , ... of Child Care Professionals (NACCP), Families ... Coalition (CIIC) are launching the second annual nationwide flu ... in Child Care Settings: Building Blocks ...
... Team by 30%, MENLO PARK, Calif., Nov. ... a leading venture capital firm celebrating,40 years of ... its,fundraising goal and closed its ninth fund at ... total capital under management to $2.6,billion. Morgenthaler Venture ...
... launched a totally new advanced skincare range that is designed ... just for ... millions of,concerned mums who have 12-24 year old boys suffering with spots ... totally new advanced skincare range that is designed,just for boys, helping to ...
... whites, 19% for blacks, 21% for Hispanics and 27% for ... -- Minority children waiting for a heart transplant have a ... eight years of data from the United Network of Organ ... 3,299 children waiting for a heart transplant. Of those, 58 ...
Cached Medicine News:Health News:Osteoporosis care at risk in the United States 2Health News:SEIU Statement in Support of New Blueprint to Solve Health Care Crisis by Senator Max Baucus 2Health News:Audio: NACCP, Families Fighting Flu, and the Childhood Influenza Immunization Coalition Team Up to Educate Families About Annual Childhood Flu Vaccination 2Health News:Audio: NACCP, Families Fighting Flu, and the Childhood Influenza Immunization Coalition Team Up to Educate Families About Annual Childhood Flu Vaccination 3Health News:Audio: NACCP, Families Fighting Flu, and the Childhood Influenza Immunization Coalition Team Up to Educate Families About Annual Childhood Flu Vaccination 4Health News:Morgenthaler Closes Ninth Fund at $400 Million 2Health News:Morgenthaler Closes Ninth Fund at $400 Million 3Health News:Morgenthaler Closes Ninth Fund at $400 Million 4Health News:OXY Launches Young Male Skincare Range - a UK First 2Health News:Death Rates Higher for Minority Children Awaiting Heart Transplant 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: